Evidence map›Paper›PMID 27805609›Full record

ArticleJournal of visualized experiments : JoVE2016

Bacterial Inner-membrane Display for Screening a Library of Antibody Fragments.

Parisa Moghaddam-Taaheri, Svetlana P Ikonomova, Zifan Gong, Janna Q Wisniewski, Amy J Karlsson

Open access · greenAbstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Parisa Moghaddam-TaaheriFischell Department of Bioengineering, University of Maryland.
Svetlana P IkonomovaDepartment of Chemical and Biomolecular Engineering, University of Maryland.
Zifan GongDepartment of Chemical and Biomolecular Engineering, University of Maryland.
Janna Q WisniewskiFischell Department of Bioengineering, University of Maryland.
Amy J KarlssonFischell Department of Bioengineering, University of Maryland; Department of Chemical and Biomolecular Engineering, University of Maryland; ajkarl@umd.edu.
University of Maryland, College Park · US

Funding

Training in Host-pathogens interactionsT32AI089621 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI LEE, VINCENT T, MCIVER, KEVIN S. · 2010 to 2025
$2.1M
Engineering intrabodies for knockdown of target proteins in cancer cellsF32CA150622 · NCI · CORNELL UNIVERSITY · PI KARLSSON, AMY J · 2011 to 2011
$49k
NCI NIH HHS F32 CA150622NIAID NIH HHS T32 AI089621
6 · The paper itself

Abstract

Antibodies engineered for intracellular function must not only have affinity for their target antigen, but must also be soluble and correctly folded in the cytoplasm. Commonly used methods for the display and screening of recombinant antibody libraries do not incorporate intracellular protein folding quality control, and, thus, the antigen-binding capability and cytoplasmic folding and solubility of antibodies engineered using these methods often must be engineered separately. Here, we describe a protocol to screen a recombinant library of single-chain variable fragment (scFv) antibodies for antigen-binding and proper cytoplasmic folding simultaneously. The method harnesses the intrinsic intracellular folding quality control mechanism of the Escherichia coli twin-arginine translocation (Tat) pathway to display an scFv library on the E. coli inner membrane. The Tat pathway ensures that only soluble, well-folded proteins are transported out of the cytoplasm and displayed on the inner membrane, thereby eliminating poorly folded scFvs prior to interrogation for antigen-binding. Following removal of the outer membrane, the scFvs displayed on the inner membrane are panned against a target antigen immobilized on magnetic beads to isolate scFvs that bind to the target antigen. An enzyme-linked immunosorbent assay (ELISA)-based secondary screen is used to identify the most promising scFvs for additional characterization. Antigen-binding and cytoplasmic solubility can be improved with subsequent rounds of mutagenesis and screening to engineer antibodies with high affinity and high cytoplasmic solubility for intracellular applications.

Indexed as

Gene LibraryImmunoglobulin FragmentsSingle-Chain AntibodiesTwin-Arginine-Translocation SystemAntigensEnzyme-Linked Immunosorbent AssayEscherichia coliPeptide LibraryAntigensImmunoglobulin FragmentsPeptide LibrarySingle-Chain AntibodiesTwin-Arginine-Translocation System

Identifiers

PMID27805609
PMCPMC5092199
OpenAlexW2531778996

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.